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Background
It has been reported that canakinumab, a monoclonal
anti IL-1 antagonist, was effective in patients with FMF
who are either non-responsive or intolerant to colchicine.
Objectives
To share our experience with canakinumab in a larger
group of FMF patients treated for diverse indications
and with a longer follow-up.
Methods
The data of the patients on canakinumab who are exam-
ined physically and checked for laboratory parameters
before each injection is evaluated with regard to response
and safety.
Results
Data of 31 (17F/14M) patients who had received more
than 3 injections of canakinumab (150mg/mo) were
included. The indications were insufficient response to
colchicine in 22 (>1 attack/month), amyloidosis in 6,
injection site reaction with anakinra in 5, and adverse
effects of colchicine in 4 patients (azoospermia and neu-
ropathy in one each, myopathy in 2). Six patients had
concomitant diseases like ankylosing spondylitis and poly-
arteritis nodosa. The mean age of the patients was 35,90
±13 years, the mean disease duration was 15±9,30 years,
the mean injection number was 9,80±6 and the mean
duration of canakinumab therapy was 16±9,26 months.
Twenty four patients had no attacks after canakinumab.
The attack frequency was reduced more than %50 in
5 patients, did not change in 2. In 6 cases with FMF
amyloidosis, proteinuria decreased in 2 (from 15020 to
1098mg/dl; from 6135 to 300mg/dl), increased in the
other 2 (from 1700 to 4700mg/dl; from 5001 to 7061
mg/dl) and was stable in the remaining 2 patients. Four-
teen patients with myalgia and calf pain unresponsive to
colchicine, improved significantly as the mean patient
global assessment score decreased from 8,25 ± 2,48 to
2,06±2,63 (p
Conclusion
Canakinumab is effective in controlling the febrile attacks
and calf pain in FMF patients with inadequate response
or intolerant to colchicine, yet its effect in amyloidosis is
variable. It seems to have an acceptable safety profile.
Further controlled studies are needed to better assess the
safety and efficacy of canakinumab in FMF.
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